 PHASE 3 STUDY OF BI 207127 IN COMBINATION WITH FALDAPREVIR AND RIBAVIRIN FOR TREATMENT OF PATIENTS WITH HEPATITIS C INFECTION, INCLUDING PATIENTS WHO ARE NOT ELIGIBLE TO RECEIVE PEGINTERFERON: HCVERSO2: 